BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. It has development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX) for marketed indications and collagenase clostridium histolyticum (CCH) for indications in development. Auxilium has an option to acquire additional indications that it may pursue, including human and canine lipoma. Auxilium is selling XIAFLEX in the United States for the treatment of Dupuytren’s contracture and Peyronie’s disease. Auxilium entered into an agreement with Swedish Orphan Biovitrum AB (Sobi) pursuant to which Sobi has marketing rights for XIAPEX (the European Union trade name for collagenase clostridium histolyticum) for Dupuytren’s contracture and Peyronie’s disease in Europe and certain Eurasian countries.